KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $11.2 million.

  • Xenon Pharmaceuticals' Gains from Investment Securities rose 155.19% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.2 million, marking a year-over-year increase of 155.19%. This contributed to the annual value of $10.7 million for FY2024, which is 2040.35% up from last year.
  • Xenon Pharmaceuticals' Gains from Investment Securities amounted to $11.2 million in Q3 2025, which was up 155.19% from $11.7 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Gains from Investment Securities high stood at $30.4 million for Q4 2024, and its period low was $5.6 million during Q4 2021.
  • In the last 5 years, Xenon Pharmaceuticals' Gains from Investment Securities had a median value of $8.8 million in 2023 and averaged $9.7 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first soared by 24196.41% in 2024, then skyrocketed by 155.19% in 2025.
  • Quarter analysis of 5 years shows Xenon Pharmaceuticals' Gains from Investment Securities stood at $5.6 million in 2021, then increased by 26.24% to $7.1 million in 2022, then increased by 24.96% to $8.9 million in 2023, then skyrocketed by 241.96% to $30.4 million in 2024, then crashed by 63.23% to $11.2 million in 2025.
  • Its Gains from Investment Securities stands at $11.2 million for Q3 2025, versus $11.7 million for Q2 2025 and $12.1 million for Q1 2025.